Spots Global Cancer Trial Database for skin
Every month we try and update this database with for skin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin | NCT02449681 | Metastatic Head... | TH-4000 (Tarlox... | 18 Years - | Rain Oncology Inc | |
| Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection | NCT01004952 | Melanoma | screening quest... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects | NCT02145130 | Burn Injury Soft Tissue Inj... Skin Necrosis Scars Congenital Gian... Skin Tumors | denovoDerm denovoSkin | 1 Year - 70 Years | University of Zurich | |
| Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects | NCT02145130 | Burn Injury Soft Tissue Inj... Skin Necrosis Scars Congenital Gian... Skin Tumors | denovoDerm denovoSkin | 1 Year - 70 Years | University of Zurich | |
| Sunitinib Treatment on Tissue Sodium Accumulation (TSS2) | NCT04368546 | Renal Cell Canc... Hypertension Sodium Imbalanc... | Sunitinib | 18 Years - 70 Years | Charite University, Berlin, Germany | |
| Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin | NCT02449681 | Metastatic Head... | TH-4000 (Tarlox... | 18 Years - | Rain Oncology Inc | |
| The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases | NCT00005660 | Basal Cell Carc... Keratosis Palma... Psoriasis | - | National Institutes of Health Clinical Center (CC) | ||
| Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100 | NCT01008527 | Melanoma | CP 870,893 Peptides Oncovir poly IC... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines | NCT00698100 | Melanoma Skin | human tyrosinas... mouse tyrosinas... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Health Communication in Families | NCT00597961 | Lung Cancer Melanoma Skin Cancer | 18 Years - | Memorial Sloan Kettering Cancer Center | ||
| Calcium Electroporation as a Treatment for Cutaneous and Subcutaneous Malignant Tumours | NCT04225767 | Cancer | Calcium electro... | 18 Years - | Zealand University Hospital | |
| Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | NCT00558103 | Neoplasms, Brea... | lapatinib Pazopanib | 18 Years - | GlaxoSmithKline | |
| Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma | NCT01005745 | Metastatic Mela... | Surgery Administration ... Adoptive Cell T... High Dose IL-2 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis | NCT02844777 | Actinic Keratos... | Placebo 5% VDA-1102 10% VDA-1102 | 18 Years - | Vidac Pharma | |
| Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC | NCT01437605 | Melanoma | MAGE-A3 ASCI in... MAGE-A3 ASCI in... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity | NCT01323517 | Melanoma | Ipilimumab, Mel... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Trial of Curcumin in Cutaneous T-cell Lymphoma Patients | NCT00969085 | Cutaneous T-cel... | Curcumin (Turme... Questionnaires Photos | - | M.D. Anderson Cancer Center | |
| Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | NCT03633110 | Cutaneous Melan... Non-small Cell ... Squamous Cell C... Urothelial Carc... Renal Cell Carc... | GEN-009 Adjuvan... Nivolumab Pembrolizumab | 18 Years - | Genocea Biosciences, Inc. | |
| Sunitinib Treatment on Tissue Sodium Accumulation (TSS2) | NCT04368546 | Renal Cell Canc... Hypertension Sodium Imbalanc... | Sunitinib | 18 Years - 70 Years | Charite University, Berlin, Germany | |
| Sunitinib Treatment on Tissue Sodium Accumulation (TSS2) | NCT04368546 | Renal Cell Canc... Hypertension Sodium Imbalanc... | Sunitinib | 18 Years - 70 Years | Charite University, Berlin, Germany | |
| Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma | NCT02131805 | Cutaneous Basal... Squamous Cell C... | Electronic Skin... Quality of life... | 60 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma | NCT03921073 | Angiosarcoma of... | T-VEC | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer | NCT00113334 | Head and Neck C... | ABT-510 | 18 Years - | M.D. Anderson Cancer Center | |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | NCT04333108 | Indolent System... | Masitinib Placebo Best Supportive... | 18 Years - 75 Years | AB Science | |
| Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma | NCT02131805 | Cutaneous Basal... Squamous Cell C... | Electronic Skin... Quality of life... | 60 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | NCT05199584 | Solid Tumors Wi... | ENV-101 (talade... | 18 Years - | Endeavor Biomedicines, Inc. | |
| Trial of Ixazomib for Kaposi Sarcoma | NCT04305691 | Kaposi Sarcoma Skin | Ixazomib Citrat... Quality-of-Life... Questionnaire A... | 18 Years - | AIDS Malignancy Consortium | |
| Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin | NCT02883556 | Carcinoma, Squa... | Pembrolizumab | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC | NCT01437605 | Melanoma | MAGE-A3 ASCI in... MAGE-A3 ASCI in... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Cancer Mortality Affected by the Choice of Anesthetic Drugs? | NCT01418326 | Breast Cancer Colo-rectal Can... Skin Cancer | - | Uppsala University | ||
| Novel Skin Care for Chemotherapy- Related Dermatologic Toxicities | NCT04929847 | Skin Toxicity | Self-prepared e... | 18 Years - | Jessa Hospital | |
| Novel Skin Care for Immunotherapy- Related Dermatologic Toxicities | NCT04929834 | Skin Toxicity Immunotoxicity | Hydrating emoll... | 18 Years - | Jessa Hospital | |
| Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study | NCT01760499 | Melanoma | PV-10 Surgery | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR | NCT00240682 | Skin Diseases Carcinoma, Squa... | cetuximab | 18 Years - | Centre Hospitalier of Chartres | |
| Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | NCT00558103 | Neoplasms, Brea... | lapatinib Pazopanib | 18 Years - | GlaxoSmithKline | |
| Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma | NCT01902225 | Lymphoma T-Cell Lymphoma Cutaneous Lymph... | Istodax Doxil | 18 Years - | University of California, San Francisco | |
| RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC | NCT05220748 | Cutaneous Squam... Head and Neck S... | RM-1995 Pembrolizumab | 18 Years - | Rakuten Medical, Inc. | |
| Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma | NCT00745862 | Melanoma | questionnaire o... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma | NCT01902225 | Lymphoma T-Cell Lymphoma Cutaneous Lymph... | Istodax Doxil | 18 Years - | University of California, San Francisco | |
| Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients | NCT00055237 | Kaposi's Sarcom... HIV Infections HIV Seronegativ... | Bevacizumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma | NCT04741997 | Melanoma Stage ... Melanoma Stage ... BRAF V600 Mutat... | Encorafenib Pil... Binimetinib Pil... Nivolumab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis | NCT00814073 | Indolent System... | Masitinib Placebo Best Supportive... | 18 Years - 75 Years | AB Science |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
